The expectation of some has changed very quickly, volume of over 1M shares is now a subdued day and anything but a 52 week high is unacceptable.
This time last month any current holder would have been satisfied with a sp over 20c with volume consistently above 1M, where nothing has fundamentally changed over this period.
In saying that, although the recent price increase has occurred over a short space of time this really ‘should’ have occurred gradually as each cohort was successfully completed. The current market cap of $100M seems about fair value for an ASX biotech pending phase II results.
LCT Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
